within Pharmacolibrary.Drugs.ATC.N;

model N05BA22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.5,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cloxazolam is a benzodiazepine derivative used as an anxiolytic and for the treatment of anxiety disorders. It has sedative and muscle-relaxant properties. The drug is no longer widely used in most countries and is not currently FDA-approved in the United States, but is still marketed in Japan and a few other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on class similarity to other oral benzodiazepines (e.g., diazepam) given the absence of direct published PK studies for cloxazolam in the literature. Assumed for a typical healthy adult population, single oral dose.</p><h4>References</h4><ol><li><p>Lavene, D, et al., &amp; Rulliere, R (1980). [Pharmacokinetics of cloxazolam in man, after single and multiple oral doses (author&#x27;s transl)]. <i>Therapie</i> 35(4) 533â€“543. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6110252/&quot;>https://pubmed.ncbi.nlm.nih.gov/6110252</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BA22;
